Tumor Biology

, Volume 36, Issue 3, pp 1773–1780 | Cite as

Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer

Research Article

Abstract

Biglycan is an important component of the extracellular matrix, which belongs to the small leucine-rich proteoglycan family. Recent studies have shown that biglycan expression is elevated in many tumor tissues and implies poor prognosis, such as colon cancer. However, the molecular mechanism of biglycan in colon cancer has not been investigated. The present study aimed to investigate the effects of biglycan on vascular endothelial growth factor (VEGF) expression in colon cancer cells and on tumor angiogenesis in vivo. Biglycan overexpression vectors were constructed, and the stable biglycan overexpression in human colon cancer cell lines (HCT116 cells) was established by G418 screening. The stable cell clones were subsequently used to initiate tumor xenografts in nude mice. Our results showed that biglycan overexpression notably up-regulated the levels of VEGF in colon cancer cells, which was further confirmed by immunohistochemistry analysis in the xenograft colon tumors. Moreover, high levels of biglycan promoted angiogenesis and colon tumor growth, as evidenced by the increased cell viability, colon tumor size, and weight, as well as the CD34 expression. Additionally, we found that the extracellular signal-regulated kinase (ERK) signaling pathway was activated by biglycan in colon cancer cells. The ERK inhibitor PD98059 dramatically reversed the increased expression of VEGF induced by biglycan. Taken together, our results indicated that biglycan up-regulated VEGF expression in colon cancer cells and promoted tumor angiogenesis. Biglycan-mediated VEGF regulation may correlate with the activation of the ERK signaling pathway. Therefore, biglycan may be a promising target for anti-angiogenic therapy for cancer.

Keywords

Biglycan Colon cancer VEGF ERK signaling pathway 

Notes

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (No. 81201968), the Natural Science Foundation of Liaoning Province (No. 201102111), and the Doctoral Starting Foundation of Liaoning Province (No. 20091045).

Conflicts of interest

None

References

  1. 1.
    Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127:679–95.CrossRefPubMedGoogle Scholar
  2. 2.
    Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol: Off J Am Soc Clin Oncol. 2005;23:1011–27.CrossRefGoogle Scholar
  3. 3.
    Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol. 2009;19:329–37.CrossRefPubMedGoogle Scholar
  4. 4.
    Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010;468:829–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.CrossRefPubMedGoogle Scholar
  6. 6.
    Wadhwa S, Embree MC, Bi Y, Young MF. Regulation, regulatory activities, and function of biglycan. Crit Rev Eukaryot Gene Expr. 2004;14:301–15.CrossRefPubMedGoogle Scholar
  7. 7.
    Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, et al. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol. 2008;49:207–16.CrossRefPubMedGoogle Scholar
  8. 8.
    Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, et al. Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. Omics: J Integr Biol. 2009;13:345–54.CrossRefGoogle Scholar
  9. 9.
    Liu Y, Li W, Li X, Tai Y, Lu Q, Yang N, et al. Expression and significance of biglycan in endometrial cancer. Arch Gynecol Obstet. 2014;289:649–55.CrossRefPubMedGoogle Scholar
  10. 10.
    Aprile G, Avellini C, Reni M, Mazzer M, Foltran L, Rossi D, et al. Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. Tumour Biol: J Int Soc Oncodev Biol Med. 2013;34:131–7.CrossRefGoogle Scholar
  11. 11.
    Hu L, Duan YT, Li JF, Su LP, Yan M, Zhu ZG, Liu BY, Yang QM: Biglycan enhances gastric cancer invasion by activating fak signaling pathway. Oncotarget 2014.Google Scholar
  12. 12.
    Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK. Hospitalizations, costs, and outcomes of severe sepsis in the united states 2003 to 2007. Crit Care Med. 2012;40:754–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Wang B, Li GX, Zhang SG, Wang Q, Wen YG, Tang HM, et al. Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer. Exp Biol Med (Maywood). 2011;236:1247–53.CrossRefGoogle Scholar
  14. 14.
    Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2003;9:207–14.Google Scholar
  15. 15.
    Yamamoto K, Ohga N, Hida Y, Maishi N, Kawamoto T, Kitayama K, et al. Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br J Cancer. 2012;106:1214–23.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res. 2007;143:58–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Liang D, Li F, Fu Y, Cao Y, Song X, Wang T, et al. Thymol inhibits LPS-stimulated inflammatory response via down-regulation of Nf-kappab and MAPK signaling pathways in mouse mammary epithelial cells. Inflammation. 2014;37:214–22.CrossRefPubMedGoogle Scholar
  18. 18.
    Gu X, Ma Y, Xiao J, Zheng H, Song C, Gong Y, et al. Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers. Clin Exp Med. 2012;12:195–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Hu L, Duan YT, Li JF, Su LP, Yan M, Zhu ZG, et al. Biglycan enhances gastric cancer invasion by activating FAK signaling pathway. Oncotarget. 2014;5:1885–96.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp. 1991;22:339–47.PubMedGoogle Scholar
  21. 21.
    Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, et al. Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem Cells Dev. 2006;15:305–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Ajili F, Kacem M, Tounsi H, Darouiche A, Enayfer E, Chebi M, et al. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34. Ultrastruct Pathol. 2012;36:336–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 2011;17:347–62.CrossRefPubMedGoogle Scholar
  24. 24.
    Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res. 1999;247:495–504.CrossRefPubMedGoogle Scholar
  25. 25.
    Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ: Mol Biol J Am Assoc Cancer Res. 1998;9:49–58.Google Scholar
  26. 26.
    Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964–8.PubMedGoogle Scholar
  27. 27.
    Berendsen AD, Pinnow EL, Maeda A, Brown AC, McCartney-Francis N, Kram V, et al. Biglycan modulates angiogenesis and bone formation during fracture healing. Matrix Biol: J Int Soc Matrix Biol. 2014;35:223–31.CrossRefGoogle Scholar
  28. 28.
    Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R, et al. ERK-MAPK signaling opposes rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell. 2006;9:33–44.CrossRefPubMedGoogle Scholar
  29. 29.
    Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem. 2001;276:49289–98.CrossRefPubMedGoogle Scholar
  30. 30.
    Wang X, Harimoto K, Xie S, Cheng H, Liu J, Wang Z. Matrix protein biglycan induces osteoblast differentiation through extracellular signal-regulated kinase and smad pathways. Biol Pharm Bull. 2010;33:1891–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Weber CK, Sommer G, Michl P, Fensterer H, Weimer M, Gansauge F, et al. Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology. 2001;121:657–67.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Xiaojing Xing
    • 1
    • 3
  • Xiaohu Gu
    • 2
  • Tianfei Ma
    • 1
  • Huinan Ye
    • 3
  1. 1.Cancer Prevention and Treatment OfficeLiaoning Cancer Hospital and InstituteShenyangPeople’s Republic of China
  2. 2.Department of Surgical OncologyLiaoning Cancer Hospital and InstituteShenyangPeople’s Republic of China
  3. 3.Department of Internal OncologyLiaoning Cancer Hospital and InstituteShenyangPeople’s Republic of China

Personalised recommendations